Cummins President and COO Rich Freeland Retiring
21.8.2019 16:00:00 EEST | Business Wire | Press release
Cummins Inc. (NYSE: CMI) announced today that President and COO, Rich Freeland will retire after forty years of service with Cummins.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190821005396/en/
Rich Freeland (Photo: Business Wire)
As part of Cummins’ successions plans, the following leadership appointments are also taking place, all of which are effective October 15.
- Distribution President Tony Satterthwaite will succeed Freeland as President and COO.
- Components President Tracy Embree will succeed Satterthwaite as Distribution Business President.
- Chief Technical Officer Jennifer Rumsey will succeed Embree as Components Business President.
- Jim Fier will succeed Rumsey as Chief Technical Officer.
“I want to personally thank Rich for his many contributions to Cummins and his friendship and support over the 25 years I have known and worked with him,” said Tom Linebarger, Chairman and CEO, Cummins Inc. “He is one of the most effective leaders in Cummins history because of his ability to connect with customers, develop our employees, and his deep understanding of nearly every element of our business. Equally impressive to me is that Rich has accomplished these things in an unassuming, humble manner. He has an unrelenting commitment to our core values and always makes the right decisions for our business, for our people and our communities. His positive impact is vast, and Rich will be missed by many, many people inside and outside of Cummins.”
“I also want to congratulate Tony, Tracy, Jennifer and Jim on their new roles,” added Linebarger. “They are all incredibly talented leaders who have demonstrated their ability to lead people, drive results and make Cummins a stronger company, and a better place to work. I am excited for each of them and looking forward to working with them as we drive our company forward focusing on our growth plans and continuing to deliver value to our customers and all our stakeholders.”
Rich Freeland:
Freeland joined Cummins in 1979 as a second shift foreman in the Parts Distribution Center in Columbus, Indiana, the day after his graduation from Purdue University. Freeland spent his entire 40-year career with Cummins. Over his career, Freeland successfully led three of Cummins’ five business segments and he was responsible for all of Cummins’ global operations as Chief Operating Officer, a position he has held since 2014. Freeland will also resign from the Board of Directors of the company, effective October 15, 2019.
Tony Satterthwaite
Tony Satterthwaite, currently the Distribution Business President that employs approximately 16,000 people worldwide, will succeed Freeland as President and Chief Operating Officer of Cummins. Satterthwaite joined Cummins in 1988 and has held leadership positions throughout the company’s businesses and operations.
Prior to his current position, Satterthwaite led Cummins Power Generation from 2008 to 2015. Under his leadership, the Power Generation business unit engineered the power industry’s only full range of large stationary generator sets to meet the U.S. Environmental Protection Agency’s current Tier 4 standards. The business won major new military contracts, expanded the product footprint and invested in new technologies.
In addition to successfully leading two global business units, Satterthwaite has worked relentlessly over his career to solve problems that drive business results and improve customer satisfaction. Satterthwaite has a strong reputation for understanding the details of Cummins’ business at all levels. He has lived for extensive periods in Asia, Europe, and the US and has visited nearly every one of Cummins’ locations throughout his long career.
Tracy Embree
Tracy Embree will succeed Sattherthwaite as Distribution Business President. Embree has led the Components Business for five years, bringing the business to record sales and profitability. Under her leadership, the component product lines expanded to include transmissions. In addition, Cummins has grown market share around the world. Embree has held many leadership roles in different areas of the business, including several critical customer-facing roles.
Jennifer Rumsey
Jennifer Rumsey will succeed Embree as Components Business President. Rumsey has served in technical leadership roles since she joined Cummins in 2000 and currently serves as Chief Technical Officer. Rumsey has held roles in engineering leadership, new product program leadership, controls, aftertreatment technology, advanced engineering, and quality. Rumsey has been involved in some of the most important products and technologies that the company has developed over the last 19 years.
Jim Fier
Jim Fier will succeed Rumsey as Chief Technical Officer. Fier has been with Cummins for more than 30 years and is a highly accomplished engineering leader. In engine development, Fier is recognized as one of the most technically skilled and experienced engineers in the industry.
Fier has demonstrated the ability to build strong teams and cultivate confidence and credibility among our customers and many different partners across the industry.
About Cummins
Cummins Inc., a global technology leader, is a corporation of complementary business segments that designs, manufactures, distributes and services a broad portfolio of power solutions. The company’s products range from diesel and natural gas engines to hybrid and electric platforms, as well as related technologies, including transmissions, battery systems, fuel systems, controls, air handling, filtration, emission solutions, and power generation systems. Headquartered in Columbus, Indiana (U.S.), since its founding in 1919, Cummins employs approximately 62,600 people committed to powering a more prosperous world through three global corporate responsibility priorities critical to healthy communities: education, environment and equality of opportunity. Cummins serves customers in approximately 190 countries and territories through a network of approximately 600 company-owned and independent distributor locations, and over 7,600 dealer locations. In 2018, the company earned about $2.1 billion on sales of $23.8 billion.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190821005396/en/
Contact information
Jon Mills
Cummins Inc.
Phone: 317-658-4540
Email: jon.mills@cummins.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Massive Gaming Secures MGA B2B License to Expand Global iGaming Partnerships23.3.2026 11:13:00 EET | Press release
Massive Gaming (MVG), a global iGaming content provider with headquarters in Australia, has secured a B2B Gaming License from the Malta Gaming Authority (MGA), marking a key milestone in the company’s expansion into regulated international markets. The MGA license enables Massive Gaming to supply its gaming content and solutions to operators licensed under the Malta regulatory framework, strengthening the company’s ability to collaborate with partners across Europe and other regulated jurisdictions. To support its regulatory expansion, Massive Gaming established MVG Malta, a dedicated entity created as part of the licensing process, and which supports the company’s broader strategy to strengthen its presence within the European iGaming ecosystem. Massive Gaming develops its gaming portfolio across three studios - Slot Mart, Whale House and Blitzcrown. All three deliver a range of gaming experiences spanning traditional slot titles, regulated market content and emerging non-traditional
LTM Expands BlueVerse ™ Tech with AppIQ, AgentIQ and FusionIQ to Accelerate AI‑Led Engineering23.3.2026 10:30:00 EET | Press release
LTM – the Business Creativity partner to the world’s largest enterprises, today announced the expansion of BlueVerseTM Tech, its AI‑led engineering platform, with the launch of AppIQ, AgentIQ and FusionIQ—three purpose‑built platforms designed to help enterprises modernize applications, orchestrate AI‑first software delivery, and engineer quality at scale. As software development evolves from human‑only execution to human + intelligent agents, traditional effort‑driven engineering and QA models are increasingly unable to keep pace. These BlueVerseTM platforms embed agentic, engineering‑aware AI across the software development lifecycle (SDLC), enabling enterprises to move faster from legacy complexity to modern, resilient, and high‑quality digital systems. AppIQ — Modernize Legacy Applications, Faster AppIQ applies AI to read and understand legacy codebases, generate documentation, map functional workflows, and produce actionable specifications for forward engineering. What previously
Galderma Receives U.S. FDA Approval for Restylane ® Contour™ for the Correction of Temple Hollowing23.3.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane Contour for the correction of temple hollowing in patients over the age of 21.1,2 This builds on its previous approvals for cheek augmentation and midface contour deficiencies, helping injectors address volume loss across key structural areas.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260322108467/en/ With the broadest Injectable Aesthetics portfolio in the industry, this follows the recent U.S. approval of Restylane Lyft for augmentation of the chin region, adding to its indications to treat the midface, facial folds and wrinkles, back of hands, and the chin.4,5 Together, these approvals demonstrate Galderma’s ongoing commitment to evolving the versatile Restylane portfolio to deliver personalized, natural-looking outcomes that meet diverse patient needs.1,4,6,7 The volume of the temples can dimi
Paving the Way for Real‑Time Earth Observation: Space Compass and SWISSto12 Sign Contract for First Commercial GEO Optical Data Relay Satellite23.3.2026 06:00:00 EET | Press release
Space Compass Corporation (“Space Compass”) and SWISSto12 SA (“SWISSto12”) announced today that they have executed a procurement contract for the first GEO optical data relay satellite. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320584108/en/ (From Left to Right): Julie Pignon, Legal Counsel, SWISSto12; 倉田 るり子 (Ruriko Kurata), Legal Counsel, Space Compass; 小松 大実 (Hiromi Komatsu), Co-CEO, Space Compass; 田中 良太 (Ryota Tanaka), Engineering Director, Space Compass; Emile de Rijk, CEO, SWISSto12; Fredrik Gustavsson, Chief Financial and Strategy Officer, SWISSto12. This agreement represents a major milestone toward the realization of Space Compass’s optical data relay service. With high-speed, high-capacity optical data relay service, Space Compass aims to transform Earth Observation from just a tracking record into a real-time decision-making tool. For SWISSto12, the contract represents further validation of the company’s a
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting20.3.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver. “At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.” Details on key data presentations at AAD include: Late-Breaking Oral Presentations Hidradenitis Suppurativa Povorcitinib in Patients With Moderate to Severe Hidradenitis Suppurativa: 54-Week Efficacy and Safety Results From the STOP-HS1 & STOP-HS2 Phase 3 Studies (Session: S034 – Late-Breaking Research: Sess
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
